Challenges Associated With Indeterminate Prostate Nodules and Increased PSA Levels

Prostate cancer (PCa) has the highest incidence rate among all cancers (233,000 men, representing 27% of all new cases) and the fourth highest mortality rate. This prevalence necessitates significant attention in the diagnosis and treatment planning. The European Randomized Study of Screening for Prostate Cancer (ERSPC) trials, at the 11-year follow-up, demonstrated that prostate cancer-related mortality was reduced by 25-31% due to screening with PSA. Proponents of PSA screening base their arguments on the results of the ERSPC trial, where the most recent follow-up at 16 years demonstrated an increased benefit as the follow-up progressed. Imaging is frequently used as a subsequent step to evaluate the cause of elevated PSA levels. Patients with low-risk prostate cancer may appropriately choose immediate treatment instead of active surveillance, including younger patients, those with high-volume Gleason 6 cancer, and those of African American ethnicity, as these patients have a higher likelihood of disease progression during their lifetime.